Longevity & AgingNovel Triple-Agonist Drug Retatrutide Achieves Bariatric Surgery-Level Weight Loss
A large phase III clinical trial called TRIUMPH-1 has shown that retatrutide, an investigational once-weekly injectable drug targeting three hormone receptors, can produce weight loss comparable to bariatric surgery. In 2,339 adults with obesity, the highest dose (12 mg) led to an average 28.3% reduction in body weight — about 70 lbs — over 80 weeks. A subset continuing for another 24 weeks lost an average of 30.3%, or 85 lbs. Beyond weight, the drug significantly reduced knee osteoarthritis pain by roughly 70% and cut sleep apnea severity by over 60%, both surpassing clinically meaningful thresholds. Researchers suggest this level of efficacy could enable a target-based treatment approach for obesity, similar to blood pressure or blood sugar targets in other chronic diseases.
